Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Thromb Res ; 119(1): 85-91, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-16499954

RESUMO

INTRODUCTION: Hormone replacement therapy is known to increase the risk of thromboembolic events. We compared the effects of HRT and raloxifene on some haemostasis variables. MATERIALS AND METHODS: In a multicenter, double-blind study, 54 healthy postmenopausal women were randomized to receive either continuous treatment with 2 mg 17beta-estradiol plus 1 mg norethisterone acetate (n=30) or 60 mg raloxifene (n=24) daily for 12 months. Blood samples were collected at baseline and at 3, 6 and 12 months to evaluate therapy effects on some haemostasis variables (factor VII, factor VIII, prothrombin fragments 1 and 2, protein C, protein C activity, protein S, thrombin-antithrombin complex, D-dimer, antithrombin, fibrinogen and plasminogen activator inhibitor). RESULTS: Both raloxifene and continuous combined hormone therapy modified the haemostasis variables toward a more prothrombotic profile. Factor VIII (p<0.01) and fibrinogen (p<0.05) plasma levels significantly increased at 6 months, prothrombin fragments 1 and 2 (p<0.05) significantly increased at 12 months, whereas protein C activity (p<0.001) and antithrombin (p<0.01) significantly decreased at 12 months in both groups. CONCLUSIONS: Our results demonstrate that raloxifene and continuous combined hormone therapy exhibit the same prothrombotic profile. Both treatments induced an increase in procoagulant parameters at 6 months and a decrease in anticoagulant parameters at 12 months.


Assuntos
Estradiol/uso terapêutico , Noretindrona/análogos & derivados , Cloridrato de Raloxifeno/uso terapêutico , Moduladores Seletivos de Receptor Estrogênico/uso terapêutico , Idoso , Índice de Massa Corporal , Anticoncepcionais Orais Sintéticos/uso terapêutico , Método Duplo-Cego , Combinação de Medicamentos , Estriol/uso terapêutico , Feminino , Hemostasia/efeitos dos fármacos , Humanos , Pessoa de Meia-Idade , Noretindrona/uso terapêutico , Acetato de Noretindrona , Pós-Menopausa , Fatores de Tempo
2.
Obstet Gynecol Surv ; 61(9): 593-601, 2006 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-16919177

RESUMO

UNLABELLED: Because women with paroxysmal nocturnal hemoglobinuria (PNH) are especially vulnerable to thromboembolic phenomena, pregnancy is a time of increased risk for both mother and fetus. However, pregnancies in affected women are rare; only case reports and small studies have been reported so far. We present the case of a 20-year-old woman with PNH who, while undergoing medical tests in preparation for a bone marrow transplant, was discovered to be pregnant. We also review the obstetric literature on pregnancy complicated by PNH, which indicates that both maternal and fetal mortality is exceptionally high (11.6% and 7.2%) with the major cause of maternal mortality being thromboembolism. Major maternal complications are more frequent postpartum (30.2%) than antepartum or intrapartum (16.3%). TARGET AUDIENCE: Obstetricians & Gynecologists, Family Physicians. LEARNING OBJECTIVES: After completion of this article, the reader should be able to recall that paroxysmal nocturnal hemoglobinuria (PNH) during pregnancy increases adverse events for both the mother and the fetus, state that maternal and fetal mortality are both high, and explain that the major complications occur in the postpartum period.


Assuntos
Hemoglobinúria Paroxística/complicações , Complicações Cardiovasculares na Gravidez/etiologia , Complicações Hematológicas na Gravidez , Tromboembolia/etiologia , Adulto , Gerenciamento Clínico , Feminino , Hemoglobinúria Paroxística/mortalidade , Hemoglobinúria Paroxística/terapia , Humanos , Período Pós-Parto , Gravidez , Complicações Cardiovasculares na Gravidez/mortalidade , Complicações Cardiovasculares na Gravidez/terapia , Complicações Hematológicas na Gravidez/mortalidade , Complicações Hematológicas na Gravidez/terapia , Fatores de Risco , Tromboembolia/mortalidade
3.
Am J Obstet Gynecol ; 194(1): 167-73, 2006 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-16389027

RESUMO

OBJECTIVE: The objective of the study was to determine the most effective fetal renal pelvis anteroposterior diameter thresholds and the best gestational age in predicting significant neonatal nephrouropathy and neonatal nephrouropathy requiring surgery. STUDY DESIGN: Eighty-three newborns with prenatal ultrasound evidence of unilateral or bilateral fetal renal pelvis dilatation (anteroposterior diameter 4 mm or more) before the 26th week of gestation were systematically and prospectively investigated prenatally and postnatally. RESULTS: Receiver operating characteristic curve analysis showed that third-trimester anteroposterior diameter cut-offs were more reliable than second-trimester cut-offs in predicting significant neonatal nephrouropathy, the best threshold being 8 mm. No significant differences were found between the 2 trimesters in the screening of fetuses at risk of neonatal nephrouropathy requiring surgery. CONCLUSION: Significant neonatal nephrouropathy is better predicted at the third trimester, the best threshold being 8 mm, but the screening of patients at greater risk of surgery is also possible during the second trimester. An anteroposterior diameter of 11 mm or more, with an odds ratio of 128.33 (95% confidence interval 11.68 to 1408.98), is a very effective cut-off and a reliable prognostic indicator of neonatal nephrouropathy requiring surgery, even before the 26th week.


Assuntos
Doenças do Recém-Nascido , Pelve Renal/diagnóstico por imagem , Pelve Renal/embriologia , Ultrassonografia Pré-Natal , Doenças Urológicas , Adulto , Feminino , Humanos , Recém-Nascido , Doenças do Recém-Nascido/diagnóstico , Nefropatias/diagnóstico , Valor Preditivo dos Testes , Gravidez , Segundo Trimestre da Gravidez , Terceiro Trimestre da Gravidez , Estudos Prospectivos , Curva ROC , Sensibilidade e Especificidade , Doenças Urológicas/diagnóstico
4.
Acta Biomed ; 75 Suppl 1: 18-22, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15301284

RESUMO

Water, basic element of amniotic fluid (A.F.), is closely related to Life, Fertility and Motherhood in several cultures and religions. Through material evidences of an essential growth medium and useful diagnostic source, a new concept grow up: the fluid as a first real environment in which fetus lives and acts. Many studies confirm that in A.F. fetus starts his character-building, his memory and his intelligence. The fluid seems to be the first means of learning and acknowledgement. Sounds, smells and tastes are perceived as well as emotions and fears. Urinoterapy and staminal cells sampling shows how A.F. can be considered as an additional terapeutic resource.


Assuntos
Líquido Amniótico/fisiologia , Desenvolvimento Embrionário e Fetal/fisiologia , Sofrimento Fetal/psicologia , Sofrimento Fetal/terapia , Água , Feminino , Humanos , Trabalho de Parto , Gravidez , Olfato , Urina
5.
J Am Assoc Gynecol Laparosc ; 10(2): 205-9, 2003 May.
Artigo em Inglês | MEDLINE | ID: mdl-12732773

RESUMO

STUDY OBJECTIVE: To evaluate the capacity of chemical dissection of tissues using a mucolytic substance, Mesna, in improving laparoscopic excision of endometriotic cysts. DESIGN: Randomized, double-blind, controlled trial (Canadian Task Force classification I). SETTING: University-affiliated training hospital. PATIENTS: Forty-four women with symptomatic ovarian endometriotic cysts. Intervention. Laparoscopic excision of endometriotic cysts in 22 women with the aid of Mesna solution and in 22 with the aid of saline solution. MEASUREMENTS AND MAIN RESULTS: In comparison with saline solution, Mesna as a chemical dissector resulted in significant reductions in operating time, in difficulty encountered by the surgeon to enucleate the cysts, and in less bleeding. No differences were found in length of hospital stay, costs of surgeries, analgesic requirement, and fever. Postoperatively, patients treated with Mesna achieved more pregnancies than those treated with saline. CONCLUSION: Chemical dissection of tissues with Mesna proved to be a safe and suitable support in laparoscopic surgery for ovarian endometriotic cysts.


Assuntos
Endometriose/cirurgia , Laparoscopia/métodos , Mesna/uso terapêutico , Cistos Ovarianos/cirurgia , Doenças Ovarianas/cirurgia , Adulto , Terapia Combinada , Dissecação , Método Duplo-Cego , Endometriose/complicações , Endometriose/patologia , Feminino , Seguimentos , Humanos , Cistos Ovarianos/complicações , Cistos Ovarianos/patologia , Doenças Ovarianas/complicações , Doenças Ovarianas/patologia , Probabilidade , Valores de Referência , Medição de Risco , Índice de Gravidade de Doença , Estatísticas não Paramétricas , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...